The Institut Pasteur du Cambodge is pleased to share our latest scientific publication in a peer-reviewed journal. This publication, is the result of a study representing several years of work from the Clinical Research Group of the Epidemiology and Public Health Unit in collaboration with health facility staff.

To our knowledge, this is the first large study evaluating an HBIg-free strategy using tenofovir disoproxil fumarate prophylaxis to prevent Mother to Child Transmission of hepatitis B in infants who did not receive immunoglobulines (HBIg), but received a first dose of vaccine within the first 2 hours of life.

The TA PROHM – ANRS 12345 study reports that in women with high HBV DNA viral load (median 7·91 log IU/mL [IQR 6·43–8·37]), it is possible to reduce HBV transmission to 0% (95% CI 0·00–1·61) if tenofovir is initiated at least 1 month before birth.

The Department of National Maternal and Child Health Center from the Ministry of health is currently implementing a real life scale up pilot of the TA PROM-ANRS 12345 Strategy in Phnom Penh heath facilities receiving pregnant women.

This is a great achievement in the benefit of the public health and of the Cambodian population.

The read the publication please click the following link: https://authors.elsevier.com/c/1f8Be5E-UoYuIJ